News & Updates

Adjuvant atezolizumab improves DFS in early-stage NSCLC
Adjuvant atezolizumab improves DFS in early-stage NSCLC
27 Oct 2021 byRoshini Claire Anthony

In patients with completely resected stage II–IIIA non-small-cell lung cancer (NSCLC) who had previously received adjuvant cisplatin chemotherapy, adjuvant atezolizumab extended disease-free survival (DFS), particularly in those with PD-L1 expression 1 percent on tumour cells, interim results of the phase III IMpower010 trial showed.

Adjuvant atezolizumab improves DFS in early-stage NSCLC
27 Oct 2021